Jagsonpal Pharmaceuticals Limited — Important, 24-10-2024: General Updates

Jagsonpal Pharmaceuticals has revised its investor presentation for unaudited financial results for Q2 and H1 FY25, correcting an error. The company reported a robust 29.2% revenue growth to ₹747 million in Q2, with a net profit increase of 53% to ₹114 million. Operating margins expanded to 24.6%. Successful integration of the Yash Pharma acquisition contributed positively, with eight out of ten top brands showing growth. The outlook remains optimistic with targeted revenue growth of over 30% for FY25.